Kairos Pharma’s (KAPA) “Buy” Rating Reaffirmed at D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $9.00 price objective on the stock.

Kairos Pharma Stock Down 4.2 %

Shares of NYSEAMERICAN:KAPA opened at $1.14 on Wednesday. Kairos Pharma has a 12-month low of $0.85 and a 12-month high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.